Roche ($RHHBY) is eyeing a new approach to diabetes. The Swiss drugmaker is wading into research that could top the GLP-1 diabetes-fighting class by adding one of the drugs to another imitation hormone, GIP, for a combination treatment. Report
Roche ($RHHBY) is eyeing a new approach to diabetes. The Swiss drugmaker is wading into research that could top the GLP-1 diabetes-fighting class by adding one of the drugs to another imitation hormone, GIP, for a combination treatment. Report